Duloxetine in the treatment of major psychiatric and neuropathic disorders. - Wikidata - wikimedia - TriplyDB

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

http://www.wikidata.org/entity/Q34770302

about

Synergistic analgesia of duloxetine and celecoxib in the mouse formalin test: a combination analysis Psychiatric disorders in children and adolescents presenting with unexplained chronic pain: what is the prevalence and clinical relevancy?Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.Experimental pain sensitivity in subjects with major depression: Many pain complaints without hypersensitivity.

P2860

Q28534142-F7D395BB-3692-44AC-9BA4-67E7ED898DD6 Q34448871-328B9DCE-9184-4852-8EC6-6A30F545D5FA Q35220015-973EFD0C-E4E3-4B32-8D86-B773F4B99047 Q37733559-E18387C7-8A43-4B68-98EF-40434EBA3435 Q38020236-60850515-65B5-42B7-82FF-8ED8471FDC53 Q40564475-1424B6BA-F9A3-42A0-9014-2EF07F0C8E9A

P2860

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

http://www.wikidata.org/entity/Q34770302

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@ast

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@en

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@nl

type

label

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@ast

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@en

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@nl

prefLabel

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@ast

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@en

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@nl

P1433

Q34770302-2DE070CD-909E-42F2-BEE8-6D47606794C5

P1476

Q34770302-EF1F5A1A-CACE-4377-A166-5B3F608483A4

P2093

Q34770302-7BE3B177-BF40-47C3-95A7-858D9D89F2E9

Q34770302-91CEFACA-7BA5-4B90-ACD0-AB376C3DF7D9

Q34770302-E36C0993-995B-49F7-908B-0F525427EF4B

P2860

Q34770302-127FA65F-C847-4340-8681-863CB51C31D3

Q34770302-169C8760-AB5F-4D9F-9C2C-AA1AD152A8C5

Q34770302-16BC22B6-D955-4809-9125-2147682AF491

Q34770302-1D8ADEB5-4574-4046-9749-66016B3DD199

Q34770302-202740F2-A9DA-4B03-B6A5-08F498072DAB

Q34770302-21FE63DA-CF85-434F-BC8A-C841CBE3B3C2

Q34770302-27AE7391-AD9A-4AC3-8CCB-94F31988AB9A

Q34770302-28F24B72-5319-4030-8E02-D5D65BE5F7DF

Q34770302-30ACE0E6-3E47-4715-9457-BDE1297B4D0A

Q34770302-30B8D978-47F4-4ED5-BC45-0340C789C3F5

P304

Q34770302-9FCD5B80-54D5-4164-BEE0-9935CA33A947

P31

Q34770302-A6D6B82A-BC1F-402D-974E-20FBC30E39E9

P356

Q34770302-8859339A-2B91-43DA-B0BC-16B6226D0E00

P433

Q34770302-1C2607ED-A266-4DA1-BD48-4F1253DC8A67

P478

Q34770302-DCCF81D3-266A-4A5B-AA65-9A3E85C004E4

P50

Q34770302-12A5E35E-F8C7-4384-A953-042FBEFADBEF

P577

Q34770302-BC450673-5DDC-4E24-AE0C-1F3A6E04695E

P5875

Q34770302-FED57E36-0B94-4522-A519-F6CE3C40CCBF

P698

Q34770302-DC4C2942-92C4-4F7D-902B-89BC1D124F1A

P356

14737175.8.4.527

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Duloxetine in the treatment of major psychiatric and neuropathic disorders.

@en

P2093

Michael Riedel

http://www.w3.org/2001/XMLSchema#string

Norbert Müller

http://www.w3.org/2001/XMLSchema#string

Rebecca Schennach

http://www.w3.org/2001/XMLSchema#string

P2860

Duloxetine in the treatment of major depressive disorder: an open-label study

Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.

Depression and pain comorbidity: a literature review.

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Quality of life in the anxiety disorders.

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

Duloxetine vs. placebo in patients with painful diabetic neuropathy.

P304

527-536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737175.8.4.527

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Jürgen Möller

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5435313

http://www.w3.org/2001/XMLSchema#string

P698

18416656

http://www.w3.org/2001/XMLSchema#string